探讨马来酸氟伏沙明合并利培酮分散片治疗强迫性障碍的疗效和安全性
To explore the efficacy and safety of fluvoxamine maleate combined with risperidone dispersible tablets in the treatment of obsessive-compulsive disorder.
ES评分 0
| DOI |
| 刊名 |
Journal of International Psychiatry
|
| 年，卷(期) |
2020, 47(2) |
| 作者 |
|
| 作者单位 |
河南科技大学第五附属医院心理一区 ;
|
| 摘要 |
目的：分析强迫性障碍患者临床治疗时采用再摄取抑制剂（SSRIs），同时联合非典型抗精神病药治疗，即马来酸氟伏沙明合并联合利培酮分散片治疗的疗效及用药安全性。方法：选取2017年1月-2019年12月期间我院120例门诊及住院强迫性障碍患者作为研究对象。按照不同治疗方案进行分组，对照组60例强迫性障碍症患者仅马来酸氟伏沙明治疗，而观察组60例强迫性障碍症患者在对照组治疗基础上联合利培酮分散片治疗，比较两组疗效。结果：观察组总有效率为96.67%（58/60），对照组85.00%（51/60），两组具显著性差异（P<0.05）。两组患者治疗前及治疗后4W、8W的Y—BOCS和 HAMA评分具显著性差异（P<0.05）；且治疗后观察组各项评分均明显低于对照组（P<0.05）。治疗过程中，两组患者不良反应率以及TESS评分均不存在显著性差异（P>0.05）。结论：马来酸氟伏沙明联合利培酮分散片对于改善强迫性障碍临床疗效具有积极作用，且此药物治疗安全性较高。
|
| Abstract |
OBJECTIVE: To analyze the efficacy and safety of SSRIs combined with atypical antipsychotics in the treatment of obsessive-compulsive disorder, i.e. fluvoxamine maleate combined with risperidone dispersible tablets. Methods: 120 outpatients and inpatients with obsessive-compulsive disorder in our hospital from January 2017 to December 2019 were selected as the study subjects. According to different treatment schemes, 60 patients with obsessive-compulsive disorder in the control group were treated only with fluvoxamine maleate, while 60 patients with obsessive-compulsive disorder in the observation group were treated with risperidone dispersible tablets on the basis of the treatment in the control group. Results: The total effective rate was 96.67% (58/60) in the observation group and 85.00% (51/60) in the control group. There was significant difference between the two groups (P < 0.05). The Y-BOCS and HAMA scores of the two groups before and after treatment were significantly different (P < 0.05), and the scores of the observation group were significantly lower than those of the control group (P < 0.05). In the course of treatment, there was no significant difference in adverse reaction rate and TESS score between the two groups (P > 0.05). CONCLUSION: Fluvoxamine maleate combined with risperidone dispersible tablets has a positive effect on improving the clinical efficacy of obsessive-compulsive disorder, and the drug treatment is safe.
|
| 关键词 |
马来酸氟伏沙明；利培酮分散片；强迫性障碍；疗效；安全性
|
| KeyWord |
fluvoxamine maleate; risperidone dispersible tablets; obsessive-compulsive disorder; efficacy; safety
|
| 基金项目 |
|
| 页码 |
319-321 |
孔惠婷*.
探讨马来酸氟伏沙明合并利培酮分散片治疗强迫性障碍的疗效和安全性 [J].
国际精神病学杂志.
2020; 47; (2).
319 - 321.